Jane Bayani

Title: Jane Bayani: Innovator in Breast Cancer Prognosis

Introduction

Jane Bayani is a prominent inventor based in Richmond Hill, Canada. She has made significant contributions to the field of cancer research, particularly in the area of breast cancer prognosis. Her innovative work focuses on improving treatment outcomes for patients undergoing endocrine therapy.

Latest Patents

Jane Bayani holds a patent titled "Gene signature of residual risk following endocrine treatment in early breast cancer." This patent describes a method for prognosing endocrine-only treatment in subjects with breast cancer. The method involves providing a tumor sample, determining the expression levels of at least 40 specific genes, comparing these levels to reference expression levels from control samples, and assessing the residual risk associated with breast cancer. This innovative approach aims to enhance the accuracy of prognostic assessments in breast cancer patients.

Career Highlights

Throughout her career, Jane has worked with esteemed organizations, including the Ontario Institute for Cancer Research. Her research has focused on developing methodologies that can lead to better treatment strategies for breast cancer patients. With her expertise, she has contributed to advancing the understanding of gene expression in cancer prognosis.

Collaborations

Jane has collaborated with notable professionals in her field, including John M S Bartlett and Cindy Q Yao. These collaborations have further enriched her research and have contributed to the development of innovative solutions in cancer treatment.

Conclusion

Jane Bayani's work exemplifies the impact of innovation in the medical field, particularly in cancer research. Her patent and contributions to breast cancer prognosis highlight the importance of genetic analysis in improving patient outcomes.